EP2702149A1 - Natural derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with a further improved immune profile - Google Patents

Natural derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with a further improved immune profile

Info

Publication number
EP2702149A1
EP2702149A1 EP12710974.2A EP12710974A EP2702149A1 EP 2702149 A1 EP2702149 A1 EP 2702149A1 EP 12710974 A EP12710974 A EP 12710974A EP 2702149 A1 EP2702149 A1 EP 2702149A1
Authority
EP
European Patent Office
Prior art keywords
lactobacillus johnsonii
strain cncm
cncm
composition
johnsonii strain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP12710974.2A
Other languages
German (de)
English (en)
French (fr)
Inventor
Raymond-David Pridmore
Francis FOATA
Michèle Delley
Ivana Jankovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Priority to EP12710974.2A priority Critical patent/EP2702149A1/en
Publication of EP2702149A1 publication Critical patent/EP2702149A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01028—D-Lactate dehydrogenase (1.1.1.28)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C2220/00—Biochemical treatment
    • A23C2220/20—Treatment with microorganisms
    • A23C2220/202—Genetic engineering of microorganisms used in dairy technology
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/151—Johnsonii
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/10—General cosmetic use
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention generally relates to the field of probiotic bacteria.
  • the present invention relates to natural derivatives of the Lactobacillus johnsonii strain CN CM 1-1225 with im proved properties.
  • the present invention relates to a natural derivative of the Lactobacillus johnsonii strain CNCM I- 1225 that is deficient in D-lactic acid production and exhibits a fu rther im proved immune profile.
  • Lactobacillus johnsonii CN CM 1-1225 also known as Lactobacillus johnsonii NCC533, or as Lactobacillus johnsonii Ljl, or as Lactobacillus acidophilus Lai, a human isolate (Bernet-Camard, M. F., et al., (1997) Appl. Environ. Microbiol. 63, 2747-2753), is a probiotic that is currently commercialized very successfully under the trademark Lcl.
  • Lactobacillus johnsonii C N C M 1-1225 has severa l we l l docu mented hea lth benefits, among them, for example activities for immunomodu lation (Hal ler, D., et al., 2000, Infect. Immun. 68:752-759; Haller, D., et al ., 2000, Gut 47:79-87; or Ibnou- Zekri, N., et al., 2003, Infect. Immun. 71:428-436), or pathogen inhibition (Bernet, M. F., et al., 1994, Gut, 35:483-489), and a long history of safe use.
  • Lactobacillus johnsonii strain CNCM 1-1225 has excellent immune- regulatory properties
  • Lactobacillus johnsonii CNCM I- 1225 One aspect that has limited the application of Lactobacillus johnsonii CNCM I- 1225 in some product categories, e.g., in products intended for young children and infants, is the prod uction of predomina ntly the D-lactic acid isomer from the fermentation of sugars.
  • Lactobacillus johnsonii CNCM 1-1225 for example, if grown in MRS medium, ferments lactose to D- and L-lactic acid in a 60:40% ratio.
  • the CODEX Infant Formula Directive recommends against the consumption of D-lactic acid and D-lactic acid producing bacteria by infants of less than three years of age due to their limited D-lactic acid elimination that may result in D-lactate acidosis.
  • the CODEX has essential ly excluded D-lactic acid producing probiotics as supplements in infant formulae but has inspired the genetic engineering of strains that produce only L-lactic acid.
  • An example of such a development is the generation of a genetical ly modified orga nism (G MO), in particu lar a genetica lly modified Lactobacillus johnsonii strain, where the d-lactate dehydrogenase (D-LDH) gene (IdhD) was isolated, and an in v/ ' iro-truncated cloned copy of the IdhD gene was used to inactivate the genomic copy by gene replacement (Lapierre, L, et al., 1999, Appl. Environ. Microbiol. 65:4002-4007).
  • G MO genetical ly modified orga nism
  • IdhD d-lactate dehydrogenase gene
  • This genetically engineered strain was only produced for laboratory purposes and has never been used in food products since its genetic material has been altered using recombinant DNA technologies and the strain is consequently considered a GMO.
  • the inventors have investigated the possibility to isolate a natural (non-GMO), viable and genetically stable variant of Lactobacillus johnsonii Lai that produces only L-lactic acid and that, has improved storage stability and an improved antiinflammatory profile.
  • the present inventors have further determined D- and L-lactic acid concentrations in MRS culture supernatant and have shown that the relative D-lactic acid concentration compared to the total lactic acid concentration in the culture supernatant is below 1.5%; namely about 1.0%.
  • a DNA sequence analysis identified predominantly point mutations in the lactate dehydrogenase gene that alter the amino acid sequence of the enzyme and hence its catalytic properties.
  • the natural derivative was shown to be viable and stable with no examples of reversion to D-lactic acid production.
  • the inventors In order to assess the anti-inflammatory profile of the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 the inventors have determined the cytokine secretion profile of human PBMCs in contact with Lactobacillus johnsonii strain CNCM 1-1225 and have compared it to the cytokine secretion profile of human PBMCs in contact with the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225.
  • Lactobacillus johnsonii CNCM 1-1225 induces less pro-inflammatory cytokines (IFN and IL-12p40) than Lactobacillus johnsonii CNCM 1-1225, while the induction of IL-10 (anti-inflammatory cytokine) was not affected.
  • one embodiment of the present invention is a natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225, wherein the derivative of the Lactobacillus johnsonii strain CNCM 1-1225 is deficient in D-lactic acid production and induces the secretion of less T helper type-1 cytokines by peripheral blood mononuclear cells than Lactobacillus johnsonii strain CNCM 1-1225.
  • “Deficient in D-lactic acid production” means for the purpose of the present invention that a strain produces less than 5%, preferably less than 2%, even more preferred less than 1.5%, and ideally about 1.1% of D-lactic acid compared to the total lactic acid production.
  • the D- and L-lactic acid concentrations can be measured in the cell-free culture supernatant.
  • the total quantity of lactic acid produced by the natural derivatives of the Lactobacillus johnsonii strain CNCM 1-1225 is initially related to cell growth. When cells enter into the stationary phase and stop dividing, they continue to metabolise sugar and produce more lactic acid. The ratio of D- and L- lactic acid produced was, however, found to be constant.
  • a "natural" derivative of the Lactobacillus johnsonii strain CNCM 1-1225 means a strain which is not considered a GMO.
  • Such a natural derivative may for example be obtained by screening colonies with are subject to changes in the genome sequence that occur naturally, e.g., due to mis-repair of damaged DNA or errors in DNA replication. This natural occurrence of errors may be enhanced by subjecting the colonies to stress conditions, for example by the application of ethyl methane sulfonate, EMS.
  • GMO 'genetically modified organism
  • nucleic acid techniques involving the formation of new combinations of genetic material by the insertion of nucleic acid molecules produced by whatever means outside an organism, into any virus, bacterial plasmid or other vector system and their incorporation into a host organism in which they do not naturally occur but in which they are capable of continued propagation;
  • a strain is considered a "derivative" of the Lactobacillus johnsonii strain CNCM 1-1225, if it has a nucleic acid identity of at least 99.95%, for example of at least 99.99%, preferably of at least 99.995%.
  • a strain is considered a derivative of the Lactobacillus johnsonii strain CNCM 1-1225 if it has no more than 500, for example no more than 100, preferably no more than 50 nucleic acid changes compared to the nucleic acid sequence of Lactobacillus johnsonii CNCM 1-1225.
  • T helper type-1 cytokines The assessment of the induction of the secretion of T helper type-1 cytokines by peripheral blood mononuclear cells is a standard procedure well known to those of skill in the art and published for example in (Miettinen, M., et al., 1998, Infection and Immunity 66:6058-6062). For example the procedure described in Example 6 may be followed.
  • Lactobacillus johnsonii strain CNCM 1-1225 of the present invention exhibited mutations in the d-ldh gene responsible for the D-lactic acid deficient phenotype.
  • the natural derivatives of the Lactobacillus johnsonii strain CNCM 1-1225 may have an altered the D-lactate dehydrogenase enzyme sequence.
  • the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 may comprise an aspartic acid to asparagine amino acid change at amino acid position 260.
  • This change in the D-lactate dehydrogenase enzyme protein sequence is based on a change in the nucleic acid sequence of the D-lactate dehydrogenase gene.
  • any natural changes in the nucleic acid sequence of the D-lactate dehydrogenase gene that inactivate the resulting enzyme may achieve the subject matter of the present invention. Also at least one deletion of one or more subsequent nucleotides within the wild-type sequence, or part or the whole of the D- lactate dehydrogenase gene may achieve the subject matter of the present invention.
  • the present inventors have analyzed the nucleic acid sequence of the D-lactate dehydrogenase gene in the natural derivative of Lactobacillus johnsonii CNCM 1-1225 of the present invention.
  • the present invention a lso relates to a natu ra l derivative of the Lactobacillus johnsonii strain CNCM 1-1225, wherein the nucleic acid sequence of the D-lactate dehydrogenase gene in the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 comprises a G to A transition at nucleic acid position 820.
  • W h i l e s u c h a c h a n ge t h at res u l ts i n t h e i n a ct iva ti on of D-lactate dehydrogenase may occur spontaneously at low frequencies in nature, it is random, and can be repaired back to the parent sequence (wild type) at the same frequency.
  • This repair frequency may even be higher if the inactivated gene imparts a growth disadvantage to the variant.
  • it is important that such a change is stable, especially as it is single base-pair change which is genetical ly less stable than a deletion.
  • the change also was found to be stable.
  • Lactobacillus johnsonii CNCM 1-4435 was deposited on February 8 th , 2011, with the Collection Nationale de Cultures de Microorganismes (CNCM), Institut Pasteur, 25 Rue du Dondel Roux, F-75724 Paris Cedex 15, France, under the Budapest Treaty.
  • CNCM Collection Nationale de Cultures de Microorganismes
  • Lactobacillus johnsonii CNCIVI 1-1225 was deposited on 30 June 1992, with the CNCM, under the Budapest Treaty.
  • Lactobacillus johnsonii CNCIVI 1-4435 contains a total of 17 nucleotide changes, including the expected change in the D lactate dehydrogenase gene responsible for the deficiency in the production of D-lactic acid by this strain. There are changes in two genes whose function is predicted to be important for growth, namely LJ0135 - asparagine synthase and LJ0354b - 50S ribosomal protein L30. The effects of the individual, and combined changes have no significant adverse effects on growth as confirmed by Lactobacillus johnsonii CNCIVI 1-4435 growth at the similar rate as Lai in MRS broth, and also achieves similar final CFU's in MRS and industrial media.
  • LJ0859 - galactokinase a gene/enzyme in the galactose fermentation operon.
  • the change lies outside of the galactokinase conserved domains but appears to reduce the enzyme activity as Lactobacillus johnsonii CNCM 1-4435 shows reduced galactose fermentation.
  • Strain Lactobacillus johnsonii CNCM 1-4435 is of interest as it contains very few n umber of secondary n ucleotide changes resulting in 12 proteins with altered sequence.
  • the natural derivatives of the Lactobacillus johnsonii strain CNCM 1-1225 in accordance with the present invention may be cultured according to any suitable method a nd may be prepa red for addition to the com positions of the present invention by freeze-drying or spray-drying for example.
  • the probiotic strain Lactobacillus johnsonii CNCM 1-1225 provides numerous well documented health benefits some of which are detailed above.
  • Probiotic means microbial cell preparations or components of microbial cells with a beneficial effect on the health or well-being of the host. (Salminen S, et al. "Probiotics: how should they be defined” Trends Food Sci. Technol. 1999:10 107-10).
  • the natural derivatives of the Lactobacillus johnsonii strain CNCM 1-1225 in accordance with the present invention may be regarded essentially as bioequivalent in view of the provided health benefits.
  • the present invention relates to a composition
  • a composition comprising the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 and/or the cell- free culture supernatant in accordance with the present invention for use in the preparation of a composition for use in a method for treatment of the human or animal body by therapy.
  • the present invention also relates to the use of a composition comprising the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 and/or the cell- free culture supernatant in accordance with the present invention in the preparation of a pharmaceutical composition or a medicament.
  • Lactobacillus johnsonii CN CM 1-1225 has been extensively studied for its probiotic-associated activities, including immunomodulation (Haller, D., et al., 2000, Infect. Immun. 68, 752-759; Haller, D., et al., 2000, Gut 47, 79-87; Ibnou-Zekri, N., et al., 2003, Infect. Immun. 71, 428-436), pathogen inhibition (Bernet, M. F., et al., 1994, G ut 35, 483-489), and epithelial cell attachment (Neeser, J.
  • the natu ral derivatives of the Lactobacillus johnsonii strain CNCM 1-1225 and/or the cel l-free culture supernatant thereof in accordance with the present invention provide the same health benefits.
  • the present invention relates to a composition
  • a composition comprising the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 and/or the cell- free cu ltu re su pernata nt in accordance with the present invention for use in the treatment or prevention of disorders linked to a weakened immune system.
  • the present invention also relates to the use of the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 and/or the cell-free culture supernatant in accordance with the present invention for the preparation of a composition to treat or prevent disorders linked to a weakened immune system.
  • Typical exam ples of disorders lin ked to a weakened imm une system may be selected from the group consisting of fl u, rhinitis, common cold, and combinations thereof.
  • Th e co m position co m prisi ng t he n atu ra l de rivative of the Lactobacillus johnsonii strain CNCM 1-1225 and/or the cell-free culture supernatant in accordance with the present invention may a lso be for use in the treatment or prevention of disorders linked to the cell attachment and cell invasion by enterovirulent bacteria or viruses.
  • the present invention also extends to the use of the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 and/or the cell-free culture supernatant in accordance with the present invention for the preparation of a composition to treat or prevent disorders linked to the cell attachment and cell invasion by enterovirulent bacteria or viruses.
  • Enteroviru lent bacteria and viruses are wel l known in the art.
  • the Eu ropean Food Safety Authority (EFSA) has pu blished such a list of pathogens in Novem ber
  • the enterovirulent bacterial or viral species may for example be selected from the group consisting of Salmonella; Campylobacter; Listeria; Escherichia coli strains, such as ETEC, EH EC, EP EC, or EI EC strains, for example; Yersinia; Shigella; Toxin producing bacteria, such as Staphylococcus aureus, Clostridium botulinum, or Bacillus cereus; Vibrio vulnifucus/parahaemolyticus; rotavirus; norovirus; verotoxigenic E.
  • the disorder linked to the cell attachment and cell invasion by enterovirulent bacterial or viral species may be selected from the group consisting of lower respiratory tract infections, gastro-intestinal tract infections, otitis media, and combinations thereof.
  • composition of the present invention may be any kind of composition as long as it is suitable for administration to humans or animals.
  • the com position of the prese nt i nve ntio n may i n pa rticu la r be to be administered orally, enterally, parenterally or topically.
  • the compositions may be provided in any galenical form normally available for the selected mode of administration.
  • composition of the present invention may be administered to any age group.
  • composition of the present invention is to be administered during the cold season, e.g., from autumn to spring.
  • composition of the present invention may also be consumed at any time. It may be preferred to consume the composition of the present invention in the morning, e.g., to boost the immune system for the day.
  • the composition may, e.g., be selected from the group consisting of food compositions, petfood compositions, drinks, dairy products, nutritional formulas, infant formulas, food additives, nutraceuticals, pharmaceutical compositions, food ingredients and/or cosmetic compositions.
  • the composition may be selected from the group consisting of acidified milk products, such as yoghurts or yoghurt drinks; or milk based powders.
  • the composition may be provided in the form of a shelf stable powder.
  • the composition may be provided with a water activity smaller than 0.2, for example in the range of 0.19-0.05, preferably smaller than 0.15.
  • Water activity or a w is a measurement of the energy status of the water in a system. It is defined as the vapor pressure of water deriving from the powder/product divided by that of pure water at the same temperature; therefore, pure distilled water has a water activity of exactly one.
  • the com positions of the present invention may be cleansing, protective, treatment or care creams, skincare lotions, gels or foams, such as clea nsing or disinfecting lotions, bath compositions or deodorant compositions.
  • they may be aqueous, aqueous-alcoholic or oily solutions, solutions or dispersions of the lotion or serum type, emulsions of liquid or semi-liquid consistency, of the milk type, obtained by dispersion of a fatty phase in an aqueous phase (O/W) or vice-versa (W/O), or suspensions or emulsions of soft, semi-solid or solid consistency, of the cream type, aqueous or anhydrous gels, microemulsions, microcapsules, microparticles, or vesicular dispersions of ionic and/or non-ionic type.
  • a topical com position according to the invention may advantageously be formulated in any galenical form that is suitable for haircare, especially in the form of a hair lotion, a shampoo, especially an antidandruff shampoo, a hair conditioner, a detangler, a hair cream or gel, a styling lacquer, a hairsetting lotion, a treating lotion, a dye composition (especial ly for oxidation dyeing) optional ly in the form of a colouring shampoo, a hair-restructuring lotion, a permanent-waving composition, a lotion or gel for combating hair loss, an antiparasitic sha mpoo or a medicated shampoo, especially an anti-seborrhoea shampoo, a scalp care prod uct, which is especially anti-irritant, anti-ageing or restructuring, or which activates the blood circulation.
  • a dye composition especial ly for oxidation dyeing
  • the proportion of the fatty phase may range from 5% to 80% by weight, and preferably from 10% to 50% by weight, relative to the total weight of the composition.
  • the oils, the emulsifiers and the coemulsifiers used in the composition in emulsion form are chosen from those conventionally used in the cosmetics and/or dermatological field.
  • the emulsifier and the coemulsifier may be present, in the composition, in a proportion ranging from 0.3% to 30% by weight, and preferably from 0.5% to 20% by weight, relative to the total weight of the composition.
  • the fatty phase may represent more than 90% of the total weight of the composition.
  • the galenic forms for topical administration may also contain adjuvants that are customary in the cosmetics, pharmaceutical and/or dermatological field, such as hydrophilic or lipophilic gel ling agents, hydrophilic or li pophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, screens, odour absorbers and dyestuffs.
  • adjuvants that are customary in the cosmetics, pharmaceutical and/or dermatological field, such as hydrophilic or lipophilic gel ling agents, hydrophilic or li pophilic active agents, preservatives, antioxidants, solvents, fragrances, fillers, screens, odour absorbers and dyestuffs.
  • the amounts of these various adjuvants are those conventionally used in the field under consideration, and are, for example, from 0.01% to 20% of the total weight of the com position . Depending on their natu re, these adjuvants may be introduced into the fatty phase and/or into the aqueous
  • fatty substances that may be used in the invention, mention may be made of m i neral oils such as, for example, hydrogenated polyisobutene and liquid petroleum jelly, plant oils such as, for example, a liquid fraction of shea butter, sunflower oil and apricot kernel oil, animal oils such as, for example, perhydrosqualene, synthetic oils, in particular Purcellin oil, isopropyl myristate and ethylhexyl palmitate, unsaturated fatty acids and fluoro oils such as, for example, perfluoropolyethers.
  • plant oils such as, for example, a liquid fraction of shea butter, sunflower oil and apricot kernel oil
  • animal oils such as, for example, perhydrosqualene
  • synthetic oils in particular Purcellin oil, isopropyl myristate and ethylhexyl palmitate
  • unsaturated fatty acids such as, for example, perfluoropolyethers.
  • Use may also be made of fatty alcohols, fatty acids such as, for example, stearic acid and such as, for example, waxes, in particular paraffin wax, carnauba wax and beeswax.
  • fatty acids such as, for example, stearic acid and such as, for example, waxes, in particular paraffin wax, carnauba wax and beeswax.
  • silicone compounds such as silicone oils and, for example, cyclomethicone and dimethicone, and silicone waxes, resins and gums.
  • emulsifiers that may be used in the invention, mention may, for example, be m a de of glyce ryl stea rate, po lyso rbate 60, th e m ixtu re of cetylstea ryl alcohol/oxyethylenated cetylstearyl alcohol comprising 33 mol of ethylene oxide, sold under the name Sinnowax AO * by the company Henkel, the mixture of PEG-6/PEG- 32/glycol stearate sold under the name Tefose * 63 by the company Gattefosse, PPG-3 myristyl ether, silicone emulsifiers such as cetyl dimethicone copolyol and sorbitan monostearate or tristearate, PEG-40 stea rate, or oxyethyle nated sorbita n monostearate (20 EO).
  • composition of the invention may also advantageously contain a spring and/or mineral water, in particular chosen from Vittel water, waters from the Vichy basin, and la Roche Posay water.
  • hydrophilic gelling agents such as carbomer, acrylic copolymers such as acrylate/alkyl acrylate copolymers, polyacrylamides, and in particular the mixture of polyacrylamide, C13-14 isoparaffin and Laureth-7 so l d u n d e r t h e n a m e Se p ige l 305 * by the company SEPPIC, polysaccharides, for instance derivatives such as hydroxyalkylcelluloses, a nd in particular hydroxypropylcellulose and hydroxyethylcellulose, natural gums such as guar gum, locust bean gum, carob and xanthan gum, and clays.
  • carboxylic polymers such as carbomer, acrylic copolymers such as acrylate/alkyl acrylate copolymers, polyacrylamides, and in particular the mixture of polyacrylamide, C13-14 isoparaffin and Laureth-7 so l d u n d e r
  • lipophilic gelling agents mention may be made of modified clays such as bentones, metal salts of fatty acids, such as aluminium stearates and hydrophobic silica, or else ethylcellulose and polyethylene.
  • compositions according to the invention may also be solid preparations constituting cleansing soaps or bars.
  • n ingestible support or carrier may be of diverse natu re depending on the type of com position u nder consideration.
  • composition according to the invention to be administered orally may be formulated for example in the form of coated tablets, gel capsules, gels, emulsions, tablets, capsules, hydrogels, food bars, compact or loose powders, liquid suspensions or solutions, confectionery products, fermented milks, fermented cheeses, chewing gum, toothpaste or spray solutions or food carriers.
  • Tablets or lozenges, oral supplements in dry form and oral supplements in liq uid form are suita ble for use as dietetic or pha rmaceutical supports or food carriers.
  • the composition may be, for example, a food su pplement, which may be formulated via the usual processes for in particular producing sugar-coated tablets, gel capsules, gels, emulsions, tablets, capsules and hydrogels allowing controlled release.
  • a microorganism according to the invention may be incorporated into all forms of food su pplements or en riched foods, for example food bars or compacted or non-compacted powders.
  • the powders may be diluted in water, soda, milk products or soya bean derivatives, or may be incorporated into food bars.
  • a microorganism of the invention may moreover be formulated with the usual excipients and components for such oral compositions or food supplements, i.e. in particular fatty and/or aqueous components, humectants, thickeners, preservatives, texturing agents, flavour enhancers and/or coating agents, antioxidants, preservatives and dyes that are customary in the food sector.
  • excipients and components for such oral compositions or food supplements i.e. in particular fatty and/or aqueous components, humectants, thickeners, preservatives, texturing agents, flavour enhancers and/or coating agents, antioxidants, preservatives and dyes that are customary in the food sector.
  • compositions are administered in an amount sufficient to at least partially cure or arrest the symptoms of a disease and its complications.
  • An amount adequate to accomplish this is defined as "a therapeutically effective dose”. Amounts effective for this purpose will depend on a number of factors known to those of skill in the art such as the severity of the disease and the weight and general state of the patient.
  • compositions according to the invention are administered to a patient susceptible to or otherwise at risk of a particular disease in an amount that is sufficient to at least partially reduce the risk of developing a disease.
  • an amount is defined to be "a prophylactically effective dose”.
  • the precise amounts depend on a number of patient specific factors such as the patient's state of health and weight.
  • compositions of the present invention comprise at least one natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 and/or the cell-free culture supernatant of the present invention in a therapeutically or prophylactically effective dose.
  • the composition may comprise the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 in accordance with the present invention in an amount of 10 6 -10 12 cfu, for example 10 8 to 10 10 cfu per daily dose.
  • L. johnsonii CNCM 1-1225 may be used in the treatment or prevention of disorders related to the immune system including infections, see WO 2010/133475, fully incorporated herein by reference. It was found that L. johnsonii CNCM 1-1225 strongly induces the constitutive hBDl expression, and that heat-treated L. johnsonii CNCM 1-1225 up- regulates hBDl more strongly than its live counterpart.
  • the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 in accordance with the present invention may also be present in a non- replicating form.
  • Non-replicating natural derivatives of the Lactobacillus johnsonii strain CNCM 1-1225 include derivatives, which have been heat treated. This includes natural derivatives of the Lactobacillus johnsonii strain CNCM 1-1225 that are inactivated, dead, non-viable and/or present as fragments such as DNA, metabolites, cytoplasmic compounds, and/or cell wall materials.
  • Non-replicating means that no viable cells and/or colony forming units can be detected by classical plating methods. Such classical plating methods are summarized in the microbiology book: James Monroe Jay, Martin J. Loessner, David A. Golden.2005. Modern food microbiology.7th edition, Springer Science, New York, N.Y.790 p. Typically, the absence of viable cells can be shown as follows: no visible colony on agar plates or no increasing turbidity in liquid growth medium after inoculation with different concentrations of bacterial preparations ('non replicating' samples) and incubation under appropriate conditions (aerobic and/or anaerobic atmosphere for at least 24h).
  • non-replicating micro-organisms do not form colonies, consequently, this term is to be understood as the amount of non replicating microorganisms that is obtained from 10 6 and 10 12 cfu/g replicating bacteria.
  • composition may also comprise the natural derivative of the Lactobacillus johnsonii strain CNCM 1-1225 in accordance with the present invention in an amount of 0,005 mg - 5000 mg, for example 0.5 mg to 50 mg, per daily dose.
  • Figure 1 shows the 'survival curve' for Lactobacillus johnsonii CNCM 1-1225 treated with ethyl methane sulfonate.
  • Figure 2 shows the molecular process of natural mutations from the oxidation of a G base to the segregation of the DNA strands resulting in a mixture of parent and modified DNA types and a mixed parent and modified colony.
  • Figure 3 shows the gene sequence of the Lactobacillus johnsonii CNCM 1-1225 D-lactate dehydrogenase gene (SEQ ID NO: 1) and the changes identified in the corresponding gene in Lactobacillus johnsonii CNCM 1-4435 being circled.
  • the translated D-lactate dehydrogenase enzyme (SEQ ID NO: 2) is also shown with the corresponding changes for Lactobacillus johnsonii CNCM 1-4435.
  • Figure 4 shows the immune profiles for Lactobacillus johnsonii CNCM 1-1225 (NCC 533) and Lactobacillus johnsonii CNCM 1-4435 (NCC 2917) on human PBMCs from four donors.
  • the values of the cytokines IFN- ⁇ , IL-12p40 and IL-10 were measured in the culture supernatants with PBMCs in culture medium as control.
  • Figure 5A shows the gene sequence of the Lactobacillus johnsonii CNCM 1-4435 D-lactate dehydrogenase gene (SEQ ID NO: 6) with the base at position 778 boxed and altered compared to the parent strain Lactobacillus johnsonii CNCM 1-1225 (G).
  • Figure 5B shows the protein sequence of the Lactobacillus johnsonii CNCM I-
  • CNCM 1-1225 cultures Samples of 100 ⁇ containing approximately 10 8 colony forming units of a 16 hr Lactobacillus johnsonii CNCM 1-1225 culture were washed 3 times with Dulbecco's phosphate buffered saline. The cells were finally suspended in 1 ml PBS and 0 or 10 ⁇ ethyl methane sulfonate added and incubated at 37°C without shaking. The treated cells were washed twice in PBS, the CFU of treated and not treated cultures determined and plotted as survivors to give the 'survival curve' shown in Figure 1.
  • the conditions producing 1% survivors were initially targeted and bracketed with time points before and after, the cells diluted and plated as single colonies on MRS plates for enumeration.
  • the remaining treated cells were the used to inoculate 10 ml of MRS broth and incubated for 16 hr growth at 37°C. The culture was then diluted and spread on MRS plates to produce individual colonies for screening.
  • G guanosine residues in double stranded DNA and typically produce single base-pair changes when resolved by DNA replication as shown in Figure 2.
  • G guanosine
  • C cytidine
  • T thymidine
  • Ethyl methane sulfonate acts by chemical oxidation of G bases and results in the same mutation profile as natural mutations, namely G to A and C to T, depending on which DNA strand is sequenced. This was confirmed later by DNA sequencing of the D-lactate dehydrogenase genes and genome sequences where the vast majority of the observed changes were either G to A or C to T.
  • Example 2 Screening of individual colonies for strains deficient in D-lactic acid production. Individual ethyl methane sulfonate treated colonies were picked into 96- well plates containing 200 ⁇ MRS broth and incubated at 37°C for 24 hr to form mini cultures. The growth of the cultures was estimated by absorbance at 620 nm using a Tecan sunrise microplate reader.
  • screening individual colonies for the prese nce of D-lactic acid it is also clea r that 'mixed' cultures containing 50% of a D-lactic acid producer and 50% of a D-lactic acid non- producer will result in a culture that is 'positive' for the presence of D-lactic acid.
  • the D-lactic acid deficient phenotype that we target is therefore considered as 'recessive' to the D-lactic acid production phenotype.
  • Example 3 Determination of D-lactic acid levels in culture medium. Cultures were grown in M RS broth at 37°C for 16 hou rs a nd the bacte ria removed by centrifugation. To determine D-lactic acid concentrations, the cell-free culture supernatants were diluted in water, analysed as described above and compared to a sta nda rd cu rve prepa red with d il utions of sodi u m D-lactic acid. L-lactic acid concentrations were determined in the same way by exchanging the enzyme D- lactate dehydrogenase with rabbit muscle L-lactic dehydrogenase and using sodium L-lactic acid as standard.
  • Lactobacillus rhamnosus NCC4007 (accession number: CGMCC 1.3724) was deposited under the Budapest Treaty in October 2004, with the China General Microbiological Culture Collection Center (CGMCC), Institute of Microbiology, Chinese Academy of Sciences, No. 1, West Beichen Road, Chaoyang District, Beijing 100101, China.
  • Lactobacillus johnsonii NCC9006 is th e stra i n d e rivi ng m Lactobacillus johnsonii Lai, as described in the article by Lapierre et al.
  • Table 1 Values of D- and L-lactic acid determined for Lactobacillus johnsonii CNCM 1-1225, Lactobacillus johnsonii CNCM 1-4435 from cell-free cultures. Included as controls are the strains NCC9006, a Lactobacillus johnsonii strain with a G MO inactivation of the D-lactate dehydrogenase gene, Lactobacillus paracasei NCC2461 and Lactobacillus rhamnosus NCC4007, both considered as L-lactic acid producing strains. Experiments were performed in triplicate and are given as the mean value plus standard deviation in brackets.
  • the results show that the D-lactic acid production values for Lactobacillus johnsonii CNCM 1-1225 are approximately 65% of total lactic acid and that the D-lactic acid production values for Lactobacillus johnsonii CNCM 1-4435 are greatly reduced.
  • the D-lactic acid production levels for Lactobacillus johnsonii CNCM 1-4435 are very low and below 1% of total lactic acid. This result is similar to the results obtained for the Lactobacillus johnsonii NCC9006 containing an inactivated D-lactate dehydrogenase gene created using gene technology methods.
  • strain Lactobacillus paracasei NCC2461 and Lactobacillus rhamnosus NCC4007 both considered as L-lactic acid producers, and which produce 3 and 3.5% D-lactic acid under these conditions, respectively.
  • strain Lactobacillus johnsonii CNCM 1-4435 can be considered as a L-lactic acid producers and phenotypically distinct from Lactobacillus johnsonii CNCM 1-1225.
  • Example 4 Identification of changes in the D-lactate dehydrogenase genes.
  • the region was amplified from one ⁇ of bacterial culture using the primers PI TCAGCACATAACCAGCAGCT (SEQ ID NO: 3) plus P2 GCAATAATACTGTCGCCGGT (SEQ ID NO: 4).
  • the amplicons were purified and sequenced with primers PI, P3 GTGTATAATAAAAGACGGTC (SEQ ID NO: 5) plus P2, compiled and analysed in the DNASTAR suite of programs. The results are shown in Figure 3.
  • the strain Lactobacillus johnsonii CNCM 1-4435 contains a G to A change at base pair 818 of Figure 3 and Figure 4A, and which results in a aspartic acid to asparagine amino acid change at position 260 (D260N) positioned outside the conserved signature domains of the D-lactate dehydrogenase enzyme sequence ( Figure 4B).
  • the gene sequencing data shows that the D-lactic acid deficient production phenotype in Lactobacillus johnsonii CNCM 1-4435 is accompanied by a corresponding change in the D-lactate dehydrogenase gene and enzyme sequence.
  • Example 5 Determination of the phenotypic stability of Lactobacillus johnsonii CNCM 1-4435.
  • lactic acid bacteria In lactic acid bacteria a single copy of D- or L-lactate dehydrogenase is essential for the production of lactic acid and the regeneration of NADH, a co-factor in this reaction, to NAD. In lactic acid bacteria this is the only route to regenerate NAD under anaerobic conditions and is essential for growth. I n the case of the D-lactic acid deficient strains there is no selective pressu re for the reversion to D-lactic acid production as the L-lactate dehydrogenase enzyme is sufficient to cover the lack of D- lactate dehydrogenase enzyme activity.
  • Example 6 Determination of the cytokine secretion profile of human PBMCs in contact with Lactobacillus johnsonii C N C M 1-4435.
  • PBMC Human peripheral blood mononuclear cells
  • H BSS Hanks balanced salt solution
  • IMDM Iscove's Modified Dulbecco's Medium
  • PBMCs (7 x 10 5 cells/well) were then incubated with Lactobacillus johnsonii CNCM 1-1225 and Lactobacillus johnsonii CNCM 1-4435 samples (7xl0 6 cfu/well) in 48 well plates for 36 h. Bacterial cell suspensions were adjusted to lxlO 8 cfu/ml based on Neubauer cell counts. The effects of bacterial samples were tested on PBMCs from 4 individual donors. After 36 h incubation, culture plates were frozen and kept at -20°C until cytokine measurement.
  • cytokines IFN- ⁇ ; IL-12p40 and IL-10
  • IFN- ⁇ cytokines
  • IL-12p40 IL-12p40
  • IL-10 cytokines in cell culture supernatants were determined by electrochemiluminescence based multiplex (Meso Scale Discovery, Gaithersburg, MD) following the manufacturer's instructions. Results are expressed as means (pg/ml) +/- SEM of 4 individual measurements (4 donors) per bacterial preparation.
  • the human PBMC assay is a well perceived in vitro test to characterize and cluster microorganisms in their ability to stimulate immune cells (also called immunoprofiling). Measurement of pro- and anti-inflammatory cytokines (see below) in cell culture supernatants allows us to define an immune profile for each microorganism or bacterial preparation. Immune profiles may be used as indicators if seeking strains with specific immune properties (strains activating the innate immunity and strains with anti-inflammatory effect for instance).
  • Lactobacillus johnsonii CNCM 1-1225 induces high levels of IL-12p40, and IFN-y compared to the control medium shown in Figure 4.
  • the immune profiles of Lactobacillus johnsonii CNCM 1-4435 was shown to be different from Lactobacillus johnsonii CNCM 1-1225 for PBMC secretion of IL-12p40 and INF- ⁇ . Lactobacillus johnsonii CNCM 1-4435 induced less IL-12p40 and INF- ⁇ secretion than Lactobacillus johnsonii CNCM 1-1225, while IL-10 was secreted as similar levels.
  • Lactobacillus johnsonii CNCM 1-4435 hence induces less pro-inflammatory cytokines (IFN and IL- 12p40) than Lactobacillus johnsonii CNCM 1-1225, while the induction of IL-10 (antiinflammatory cytokine) is not affected.
  • Lactobacillus johnsonii CNCM 1-4435 may retain its immune-regulatory properties (homeostasis in mucosae for instance) and be more anti-inflammatory than Lactobacillus johnsonii CNCM 1-1225.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP12710974.2A 2011-03-29 2012-03-29 Natural derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with a further improved immune profile Withdrawn EP2702149A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP12710974.2A EP2702149A1 (en) 2011-03-29 2012-03-29 Natural derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with a further improved immune profile

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11160144 2011-03-29
PCT/EP2012/055675 WO2012130968A1 (en) 2011-03-29 2012-03-29 Natural derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with a further improved immune profile
EP12710974.2A EP2702149A1 (en) 2011-03-29 2012-03-29 Natural derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with a further improved immune profile

Publications (1)

Publication Number Publication Date
EP2702149A1 true EP2702149A1 (en) 2014-03-05

Family

ID=45894487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12710974.2A Withdrawn EP2702149A1 (en) 2011-03-29 2012-03-29 Natural derivative of the lactobacilus johnsonii strain cncm i-1225, deficient in d-lactic acid production and with a further improved immune profile

Country Status (8)

Country Link
EP (1) EP2702149A1 (zh)
CN (1) CN103649306B (zh)
AU (1) AU2012234193B2 (zh)
BR (1) BR112013024831A2 (zh)
CL (1) CL2013002803A1 (zh)
MX (1) MX2013011236A (zh)
SG (1) SG193589A1 (zh)
WO (1) WO2012130968A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015021530A1 (en) 2013-08-12 2015-02-19 Mansel Griffiths Antiviral methods and compositions comprising probiotic bacterial molecules
CN113234643B (zh) * 2021-06-30 2022-11-01 江南大学 一株可缓解etec致腹泻的约氏乳杆菌及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737853T2 (de) * 1997-05-03 2008-03-06 Société des Produits Nestlé S.A. Herstellung von L(+)-Lactat
AU4059999A (en) * 1998-06-05 1999-12-30 Wakamoto Pharmaceutical Co., Ltd. Lactic acid bacterium-containing compositions, drugs and foods
EP1513940A4 (en) * 2002-05-30 2006-10-25 Cargill Dow Llc METHOD AND MATERIALS FOR THE PRODUCTION OF MILKY ACID IN YEAST
AU2006291566A1 (en) * 2005-06-02 2007-03-22 Cargill, Inc. Genetically modified yeast of the species issatchenkia orientalis and closely related species and fermentation processes using same
ZA200800978B (en) * 2005-08-19 2009-08-26 Unilever Plc Food products comprising probiotic micro-organisms and antibodies
WO2010027344A1 (en) * 2008-09-04 2010-03-11 Om Pharma Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof
AU2010247469B2 (en) 2009-05-11 2014-12-18 Société des Produits Nestlé S.A. Lactobacillus johnsonii La1 NCC533 (CNCM I-1225) and immune disorders

Also Published As

Publication number Publication date
CN103649306A (zh) 2014-03-19
CL2013002803A1 (es) 2014-06-06
SG193589A1 (en) 2013-10-30
MX2013011236A (es) 2013-10-17
WO2012130968A1 (en) 2012-10-04
AU2012234193B2 (en) 2016-07-21
CN103649306B (zh) 2015-07-01
AU2012234193A1 (en) 2013-10-10
BR112013024831A2 (pt) 2016-12-20

Similar Documents

Publication Publication Date Title
WO2012130965A1 (en) Natural derivative of a well known and successful probiotic strain deficient in d-lactic acid production
CN111388402B (zh) 一种对皮肤有益的含有高浓度益生菌的组合物
EP3704958A1 (en) Muscle-building composition
AU2012234193B2 (en) Natural derivative of the Lactobacilus johnsonii strain CNCM I-1225, deficient in D-lactic acid production and with a further improved immune profile
KR20230129163A (ko) 리보플라빈 생산성이 높은 리모실락토바실러스 류테리균주 및 이의 용도
EP2697371B1 (en) Lactobacillus johnsonii strain cncm i-4437, deficient in d-lactic acid production and with an improved shelf life
WO2023281787A1 (ja) スペルミジンを菌体外に生産する乳酸菌
JP7559318B2 (ja) 皮膚細菌叢向上剤及び皮膚細菌叢向上用皮膚外用剤
EP2691549A1 (en) Natural derivate of the lactobacillus johnsonii strain cncm 1-1225 deficient in d-lactic acid production
KR102441226B1 (ko) 혼합 프로바이오틱스 발효물을 포함하는 피부 마이크로바이옴 개선용 조성물 및 이를 포함하는 화장료 조성물
KR102049970B1 (ko) 락토바실러스 카제이 hy2782를 유효성분으로 함유하는 미세먼지로 인한 산화적 스트레스를 개선하기 위한 조성물
JP2019218280A (ja) 入浴用組成物
JP7337878B2 (ja) 免疫賦活化作用を有する乳酸菌
JP6928195B1 (ja) 免疫鎮静作用を有する乳酸菌
KR20230161901A (ko) 락토바실러스 사케이 cvl-001에 의해 인터루킨 10 생산이 증가된 중간엽 줄기세포를 유효성분으로 포함하는 염증성 질환 예방 또는 치료용 약학 조성물
JP2022117889A (ja) 酸化ストレス抵抗性付与能（ｉｌ－８抑制能）及び小腸幹細胞遺伝子調節機能を有する乳酸菌

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131029

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20151211

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20160707

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161118